<DOC>
	<DOCNO>NCT01931748</DOCNO>
	<brief_summary>The Purpose study evaluate randomize , double-blind , Parallel , Non-inferiority , Multicenter , efficacy safety UNCNT comparison active comparator MELSMON female menopausal syndrome . Patients allocate randomly receive either UNCNT MELSMON . Through injection UNCNT female menopausal disorder , efficacy improvement menopausal symptom Kupperman index evaluate compare MELSMON .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Parallel , Non-Inferiority , Multicenter Trial Evaluate Efficacy Safety UNCNT Compared MELSMON Female With Menopausal Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>Woman ≥ 40 year old Corresponding one follow criterion : Postmenopausal woman 1. spontaneous amenorrhea 12 month 2 . Blood serum FSH concentration exceed 40mlU/mL , spontaneous amenorrhea 6month 3. pass least 6 week bilateral ovariectomy 4 . History bilateral hysterectomy paste least 6week blood serum FSH 40mLU/ml Confirmed use hot flash record daily diary visit 2 : More 34 ( times/ per day ) moderate severe flush least day occurrence 20 time week check flush Kupperman Index Score ≥ 15 point Serum Estradiol ≤ 30pg/mL Able communicate conduct clinical trial accord protocol Informed consent oneself Allergic drug ingredient Psychological menopausal disorder History carcinoma liver cancer etc In investigator 's judgment , unable participate study uncontrolled hypertensive ( 170/110mmHg ) , severe disease ( eg. , cardiovascular , liver , kidney ) diabetic mellitus History hysterectomy bilateral ovariectomy within 6 week Patients whose blood serum AST/ALT , bilirubin creatinine two time normal maximum rate . Receiving hormone therapy estrogen , progestin hormone class within month Patients participate clinical trial , receive investigational product within 3 month . Usage prohibit combination dig history alcohol drug abuse Washout requirement hormone therapy estrogen product involve like estrogen/progestin component ( If washout period follow criterion , subject participate study ) 1. hormonal vaginal formulation ( ring , cream , gel , etc ) ≥ 1 week 2. estrogen single agent estrogen/progestincontaining subcutaneous formulation ≥ 4 week 3 . Oral estrogen progestin therapy ≥ 8 week 4 . Progestin intrauterine therapy ≥ 8 week 5. single injection estrogen progestin formulation transplant ≥3 month 6. injection progestin estrogen pellet method ≥ 6 month In woman ≥40 age , know suspicion breast cancer Breast angiographic normal pregnancy breast test within 9 month ; history breast cancer ; Family history breast cancer one generation In Thickness uterine intima ≥5mm determine TUVS , know suspicion endometrial hyperplasia endometrial cancer perform endometrial biopsy know suspicion Cervical cancer pap test ( pap smear ) otoscleorsis Taking rifampicin induce liver microsome enzyme ( eg. , Barbiturates , Hydantion , carbamazepine , mepeu donkey mate , John diphenyl butadiene ) Jaundice , DubinJohnson syndrome Rotor syndrome Vaginal bleeding unknown reason Sickle cell anemia Severe metabolic disorder ( eg. , porphyria.. ) Thrombotic phlebitis , thrombosis , embolism patient , patient history Cerebral , coronary altery disease Thyroid disease , infectious disease Experience use placenta drug Other circumstance make investigator expect incomplete study participation patient</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>